News Column

New Genetics and Dyslipidemias Findings from Federal University Reported [Thrombin-activatable fibrinolysis inhibitor (TAFI) levels and its...

July 30, 2014



New Genetics and Dyslipidemias Findings from Federal University Reported [Thrombin-activatable fibrinolysis inhibitor (TAFI) levels and its polymorphism rs3742264 are associated with dyslipidemia in a cohort of Brazilian subjects]

By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Nutritional and Metabolic Diseases and Conditions have been published. According to news reporting from Belo Horizonte, Brazil, by NewsRx journalists, research stated, "Dyslipidemia, a metabolic alteration that affects lipoprotein levels, is considered a major risk factor for atherosclerosis and its complications. Dyslipidemia also affects the hemostatic system, especially impairing fibrinolysis, and increased levels of thrombin-activatable fibrinolysis inhibitor (TAFI) have been associated with cardiovascular events."

The news correspondents obtained a quote from the research from Federal University, "Objectives and methods: This study evaluated the association of acquired risk factors ( hypertension, body mass index - BMI, smoking, sedentary lifestyle, use or not of oral contraceptives and hormone replacement therapy, and post-menopause status), the polymorphisms Thr325lle (rs1926447), Ala147Thr (rs3742264) and + 1542C/G (rs940) in the TAFI gene, and TAFI plasma levels in 109 dyslipidemic and 105 normolipemic individuals. Biochemical analyses and TAFI levels were evaluated by colorimetric/turbidimetric assays and ELM, respectively. Genotypic and allelic frequencies were determined by polymerase chain reaction (PCR). Hypertension, increased BMI, and menopause were more common in dyslipidemic individuals, who had higher TAFI levels. The alleles 325lle, Ala147, and C showed association with lower TAFI levels. The rs3742264 polymorphism was associated with dyslipidemia in males."

According to the news reporters, the research concluded: "The results suggest that TAFI levels are independently associated to dyslipidemia and that the polymorphism rs3742264 may be related to cardiovascular risk in male subjects."

For more information on this research see: Thrombin-activatable fibrinolysis inhibitor (TAFI) levels and its polymorphism rs3742264 are associated with dyslipidemia in a cohort of Brazilian subjects. Clinica Chimica Acta, 2014;433():76-83. Clinica Chimica Acta can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Clinica Chimica Acta - www.elsevier.com/wps/product/cws_home/506018)

Our news journalists report that additional information may be obtained by contacting I.R. Santos, Federal University of Minas Gerais, Colegio Tecn, BR-31270901 Belo Horizonte, MG, Brazil. Additional authors for this research include A.P. Fernandes, M.G. Carvalho, M.O. Sousa, C.N. Ferreira and K.B. Gomes (see also Nutritional and Metabolic Diseases and Conditions).

Keywords for this news article include: Belo Horizonte, Brazil, South America, Blood Coagulation Factors, Cardiology, Cardiovascular, Dyslipidemias, Enzymes and Coenzymes, Fibrinolysis, Genetics, Nutritional and Metabolic Diseases and Conditions, Peptide Hydrolases, Serine Endopeptidases, Thrombin

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters